Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Apr 2023 Results assessing efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in adult patients with episodic migraine presented at the 75th Annual Meeting of the American Academy of Neurology 2023
12 Jun 2022 Primary endpoint (Mean Change from Baseline in the Number of Monthly Migraine Headache Days (MHDs)) has been met, according to Results presented at the 64th Annual Scientific Meeting of the American Headache Society.
12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com